anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endometrial cancer (EC) or carcinoma of corpus uteri is a neoplastic change, mostly adenocarcinoma, arising from uterine columnar epithelial lining. Abnormal uterine bleeding is the main presenting symptom especially in postmenopausal women. EC is estimated to be the seventh most commonly diagnosed cancer in women. It is considered the 16th leading cause of death in women with cancer worldwide, with 382 000 estimated new cases and 89 900 deaths in 2018. Factors as obesity, parity, diabetes mellitus, unopposed estrogen exposure, genetics and hormonal therapies are recognizable risks for EC. Other factors as chronic comorbidities, tumor size and organ metastasis influence staging, prognosis, and management protocols.

FIGO staging has been adopted as the standard classification system in the management of endometrial cancer. However, this staging system does not consider all factors that affect treatment decision and prognosis including but not limited to patient demographics, tumor grade, and lymphovascular space invasion. In addition, some interventions are still debatable particularly in the presence of intermediate disease e.g, grade II early EC. Available evidence supports combined pelvic and para-aortic lymphadenectomy in management of patients with EC. However, combined pelvic and para-aortic lymphadenectomy carry the risk of long term morbidities as lymphedema. Thus, hysterectomy alone as management plan is suggested in patients with low risk EC. More comprehensive studies of the multiple confounders that determine patient's risk are essential to reach an individually adjusted management plans and to predict prognosis of each individual case. Therefore, availability of large multicenter studies will provide robust evidence regarding optimal management of EC and hence, improve treatment outcome and prognosis particularly in the era of machine learning and artificial intelligence.
Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
Biopsies will be collected from patients that have been diagnosed with gastroparesis (having nausea, retching, bloating and fullness of stomach) and are undergoing surgery for the GES implantation. These patients will serve as our study group population. Biopsy samples of those who do not have gastroparesis but are undergoing surgery on the digestive system will be collected after the patients consent to be on the trial. These patients will serve as our control group population. Detailed medical history will be collected and the study group patients will be asked to complete two questionnaire to assess the severity of the symptoms. They will be followed in the clinic at 6, 12, 18 and 24 months post implantation.
The invention discloses an active biological peptide nutrient solution. The nutrient solution is prepared from green and pollution-free raw materials, is natural, green, and environment-friendly, and does not have any side or toxic effect to skin. The nutrient solution can properly activate the proliferation of skin stem cells so as to accelerate the metabolism of skin cells, the skin becomes young, and the effect is prominent. Moreover, the nutrient solution can supply enough ATP energy to sustain the normal operation of skin cells, protects skin cells from oxides, maintains the skin water to ensure that the interstitial fluid of skin is sufficient, creates a pH neutral micro environment of sin, and guarantees that skin cells can play important physiological functions. The provided skincare product is a comprehensive and complete nutrient system, and can protect the DNA in skin cell nucleus, modulate the cell proliferation in the gene level, activate the cell metabolism functions, and enhances the energy supply of cells. The nutrient solution can maintain the stability of skin tissue structure.
FIELD: phytotherapy; may be used in restoration of organism normal functions. SUBSTANCE: method includes vegetarian dietetics and cleaning of digestive system organs by enteroclysis in the morning and repeated peroral administration during the day of dry powders of medicinal herbs with interval of 2 h between administration, and in the evening, administration of vegetable oil with subsequent heating of liver region. The essence of the method consists in use of medicinal herbs bioenergetically compatible (adaptogenic) with patient's organism by sign of the Zodiac. Purgation is began by administration of 50 g of castor oil at the evening of the first day. During subsequent three days, daily purgation procedure includes sevenfold administration of the powders with subsequent administration of oil balsam and 5 g of powder of medicinal herbs every 3 h. Daily purgation is ended in peroral administration of purgative. Vegetarian dietetics includes vegetable products bioenergetically compatible with patient's organism by sign of the Zodiac. Energy contribution of vegetable products is equal to 80% of the daily requirements of organism. EFFECT: stable therapeutic effect. 9 cl, 1 tbl
An emerging neurological tool, called transcranial Direct Current Stimulation (tDCS), has recently been shown to safely and effectively enhance cognition in healthy individuals, as well as reduce key symptomatology in disorders such as stroke and depression, with only negligible side effects. tDCS delivers low-amplitude current to the scalp using small electrodes and part of this current passes through the skull and modulates neural activity in the underlying brain region. How this tiny amount of electric current acts to improve cognitive function and reduce symptoms (e.g., motor impairments in stroke patients with a lesion in motor brain areas) is currently unknown, although many investigators across the world are now working on this problem. Magnetoencephalography (MEG) offers a unique view of neural function, as it can delineate changes in active brain regions with excellent temporal resolution (\< 1 ms) and high spatial accuracy (2-3 mm). MEG non-invasively measures the magnetic fields that emanate from active neocortical cells. The potential of the MEG technique to precisely monitor the neural effects of tDCS shows extreme promise, but to date the method has been rarely utilized in this area.

Under this protocol, Modulation of Spontaneous Cortical Activity by tDCS: BRAIN Initiative I, approximately 124 participants will provide written informed consent, undergo cognitive and behavioral testing and a structural MRI during a single visit, and then return several weeks later (2-4 weeks) to complete a short tDCS session followed by a MEG recording (i.e., after tDCS). Most participants will return for two more visits, each separated by 2-4 weeks, that include a tDCS session followed by a MEG recording (i.e., 4 total visits). The three tDCS-MEG visits will be identical except that the nature of the stimulation (e.g., location, amplitude, direction/polarity) will be different.
Abnormal temperature in preterm infants is associated with increased morbidity and mortality. Infants born prematurely are at risk of abnormal temperature immediately after birth in the delivery room (DR). The World Health Organization (WHO) recommends that the temperature of newly born infants is maintained between 36.5-37.5oC after birth. When caring for very preterm infants, the International Liaison Committee on Resuscitation (ILCOR) recommends using a combination of interventions to prevent heat loss. While hypothermia remains prevalent, efforts to prevent it have increased the incidence of hyperthermia, which may also be harmful. Delayed cord clamping (DCC) for preterm infants has been recommended by ILCOR since 2015. Little is known about the effect of timing of DCC on temperature, nor have there been specific recommendations for thermal care before DCC. This review article focuses on the current evidence and recommendations for thermal care in the DR, and considers thermoregulation in the context of emerging interventions and future research directions. IMPACT: Abnormal temperature is common amongst very preterm infants after birth, and is an independent risk factor for mortality. The current guidelines recommend a combination of interventions to prevent heat loss after birth. Despite this, abnormal temperature is still a problem, across all climates and economies. New and emerging delivery room practice (i.e., delayed cord clamping, mobile resuscitation trolleys, early skin to skin care) may have an effect on infant temperature. This article reviews the current evidence and recommendations, and considers future research directions.
BACKGROUND: Prognostic implications of peritoneal washing cytology (CY) in patients with localized pancreatic ductal adenocarcinoma (PDAC) undergoing surgical resection following preoperative chemoradiotherapy (CRT) remain unclear. This study aimed to elucidate the prognostic significance and predictors of a positive CY status (CY+) after preoperative CRT.
METHODS: Clinical data from 141 patients with localized PDAC who underwent curative-intent resection after preoperative CRT were retrospectively analyzed to examine the association between CY+ and clinicopathological factors and survival.
RESULTS: CY+ was observed in six patients (4.3%). The CY+ group exhibited significantly higher preoperative serum levels of CA19-9 and a substantially greater incidence of tumor location in the pancreatic body or tail, along with pathological invasion to the anterior pancreatic capsule, than the CY- group. The CY+ group had a significantly higher incidence of peritoneal recurrence compared with the CY- group (83.3% vs. 18.5%, p = 0.002). Overall survival (OS) and recurrence-free survival (RFS) after surgery were significantly shorter in the CY+ group than in the CY- group (CY+ vs. CY-: 18.3 vs. 46.2 months, p = 0.001, and 8.9 vs. 17.7 months, p = 0.009, respectively). Multivariate analyses identified CY+ as an independent prognostic factor for worse OS (hazard ratio 5.00, 95% confidence interval 1.03-12.31) and RFS (hazard ratio 2.58, 95% confidence interval 1.04-6.43). Local invasion grade on imaging before CRT, limited histological response to CRT, and absence of adjuvant chemotherapy were independent predictors of worse OS and RFS.
CONCLUSION: Despite the relatively low incidence of CY+ after preoperative CRT, it emerged as an independent prognostic factor in patients with localized PDAC undergoing curative-intent resection following preoperative CRT.
Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition 5 comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of 10 the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, 15 endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or contact lens. 3280427v1
The invention relates to methods for increasing the safety of laboratory-produced cellular products ( "tissue engineered products"  (TEP)). The increased safety of such products is achieved by preventing the formation of tumors. The present invention provides a plurality of methods therefor which are based on the irradiation of the TEPs. This irradiation inactivates mitotic cells in the TEP, while the biological functions of the TEP are at least substantially preserved. Some methods of the present invention also include regeneration of the TEP following irradiation. The present invention makes it possible to produce TEPs with no resulting tumor formation, but which nevertheless exhibit biological functions and are therefore ideally suited to transplantation or drug development.
The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
A deskewing buffer system includes a plurality of storage registers each of which include a plurality of storage devices. Pairs of the storage devices provide storage for a single information channel. The devices of each channel further includes circuits for detecting when no information has been stored by an input pair of storage devices of a channel within a bit interval which signals a dropped bit within the channel. The detection circuits are then operative to switch both input storage devices of the channel to the same predetermined state. Thereafter, checking circuits coupled to a last register of the buffer system are operative to check the deskewed contents of the register and generate a signal indicating whether the channel dropped a binary ONE or binary ZERO bit. The signal is then used to transfer selectively the state of one of the pairs of storage devices of the channel to an output register.
This is a blinded randomized prospective study comparing two postoperative leg sleeves. The novel bioactive sleeve (Reparel Leg Sleeve) will be compared to a regular black sleeve with a similar feel/compression. The main hypothesis for this study is that postoperative use of a novel bioactive sleeve after partial arthroscopic meniscectomy/meniscus repair will decrease pain and improve patient reported outcome scores faster and more reliably than the control non-bioactive sleeve. In order to test this hypothesis, approximately 100 patients scheduled for meniscectomy/meniscus repair will be randomized to one of the two arms in order to minimize bias. The following variables will be assessed: patient reported outcomes (VAS, KOOS JR, VR12, and KSS Satisfaction), physical therapy time, motor testing. Each patient will fill out a series of PROMs preoperatively, and post operatively at the 1-week, 2-week, 6-week, 3-month, 6-month, 1 year, and 2-year mark.
Participants look at an external screen displaying the VR avatar participant's arms while performing wrist dorsiflexion MI in random order (left or right). The BCI system detects the ERD of the motor area corresponding to correct MI. Then, visual feedback with the VR and motor-tactile feedback with the discharge of the FES is delivered. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
The concept of femoral neck preserving hip replacement is intended for the young and active patients. By preserving proximal bone load, the transmission to the proximal femur is supposed to improve and future revision surgery would be facilitated. The hypothesis is that a more conservative resection of the femoral neck could lead to better clinical outcomes compared to a conventional stem. The clinical outcomes and the fixation of a short femoral stem were therefore compared with a stem of standard length. 83 patients were included in our randomized controlled trial where patients either received a Collum Femoris Preserving (CFP) stem or a Corail hip stem. Clinical outcomes are being assessed, plain radiographs are studied and the early migration is being measured using radiostereometric analysis. All of the patients have gone through 1 year follow-up. The 2 years results will be available at the end of 2017.
Provided are synthesis and application of bornyl ferulate. A synthesis technology enables ferulic acid, protected by a phenolic hydroxyl group, and borneol to perform condensation reaction, and an obtained product is de-protected to obtain bornyl ferulate. Another synthesis technology performs reaction between halogenated bornyl acetate and an organophosphorus agent, and then performs wittig reaction between an obtained wittig phosphorous agent and 3-methoxyl-4-hydroxy benzaldehyde, so as to obtain bornyl ferulate. The synthesis technologies of the present invention are simple, raw materials are economic, easy to obtain, non-toxin and harmless, and the synthesis process is easy to control and applicable to large-scale industrial production. In addition, the present invention also provides application of bornyl ferulate in preparation of a medicine for treating cerebrovascular diseases. Specifically, the inventor discovers that the bornyl ferulate is capable of effectively relieving the brain blood circulation disorder disease of a patient with stroke, achieves a good protection effect on brain nerves of the patient, and has a good clinical application prospect.
Neuropathic pain (NP), a severe chronic pain condition, remains a substantial clinical challenge due to its complex pathophysiology and limited effective treatments. An association between the members of the Fibroblast Growth Factors (FGFs), particularly Fgf3, and the development of NP has become evident. In this study, utilizing a mouse model of NP, we observed a time-dependent increase in Fgf3 expression at both mRNA and protein levels within the dorsal root ganglia (DRG). Functional studies revealed that blocking Fgf3 expression mitigated nerve injury induced nociceptive hypersensitivity, suggesting its pivotal role in pain modulation. Moreover, our findings elucidate that Fgf3 contributes to pain hypersensitivity through the activation of the Akt/mTOR signaling in injured DRG neurons. These results not only shed light on the involvement of Fgf3 in nerve injury-induced NP but also highlight its potential as a promising therapeutic target for pain management. This study thereby advances our understanding of the molecular mechanisms underlying NP and opens new avenues for the development of effective treatment strategies.
NEW MATERIAL:The compound of formula I (R<1> and R<2> are H, lower alkoxy or halogen; R<3> is H or lower alkyl; A is H, lower alkyl, etc.; n is 0-2) and its salt. EXAMPLE:2-Mercapto-4,5-diphenylimidazole-1-acetic acid ethyl ester. USE:An anti-inflammatory and analgesic agent. PREPARATION:The objective compound such as the compound of formula Ia can be produced by reacting a compound of formula II with a compound of formula III in a proper solvent in the presence of a base under heating to produce an amino ketone as an intermediate, adding a thiocyanic acid salt to the ketone and heating the mixture. The reaction solvent is e.g. methanol or ethanol.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, oncology, and can be used for photothermolysis of cancer cells. For this purpose colloidal solution of mixture of glycerol and physiological solution with gold nanoparticles is introduced. Cancer cells are irradiated with resonance pulse laser radiation. Gold nanoparticles represent gold nanoshells or nanorods. Plasmon resonance of nanoparticles has spectral maximum of absorption in area of biotissure transparency at wavelength 750-1200 nm. Concentration of nanoparticles is selected in range 5107 -5109 cm-3 depending on tumour location depth. Ratio of glycerol with physiological solution is selected in such a way that index of solution refraction at the wavelength of resonance laser irradiation was the nearest to index of irradiated tissue refraction. Irradiation of cancer cells is carried out by laser beam with irradiation wavelength coinciding with spectral area of plasmon resonance. For local destruction of cancer cells irradiation is performed by sequence of laser pulses with laser pulse duration in range 1mcs-1ms with minimal porosity two and more. Power density constitutes not more than 10 W/cm. ^ EFFECT: method makes it possible to carry out photothermolysis of volumetric tumours on surface and in the depth of biotissues with minimal damage to normal cells. ^ 7 dwg
INTRODUCTION: Atorvastatin (ATV), a medication used to reduce cholesterol levels, possesses properties that can counteract the damaging effects of free radicals and reduce inflammation. However, the administration of ATV orally is associated with low systemic bioavailability due to its limited capacity to dissolve in water and significant first-pass effect. This study aimed to assess the appropriateness of employing nano-vesicles for transdermal administration of ATV in order to enhance its anti-inflammatory effects.
METHODS: ATV-loaded transethosomes (ATV-TEs) were optimized using the 33 Box-Behnken design. The ATV-TEs that were created were evaluated for their vesicle size, encapsulation efficiency (% EE), and percent release of drug. The optimum formulation was integrated into a hydroxypropyl methylcellulose (HPMC) emulsion-based gel (ATV-TEs emulgel) using jojoba oil. ATV-TEs emulgel was examined for its physical characteristics, ex vivo permeability, histological, and anti-inflammatory effect in a rat model of inflamed paw edema.
RESULTS: The optimized transethosomes exhibited a vesicle size of 158.00 nm and an encapsulation efficiency of 80.14 ± 1.42%. Furthermore, the use of transethosomal vesicles effectively prolonged the release of ATV for a duration of 24 hours, in contrast to the pure drug suspension. In addition, the transethosomal emulgel loaded with ATV exhibited a 3.8-fold increase in the transdermal flow of ATV, in comparison to the pure drug suspension. ATV-TEs emulgel demonstrated a strong anti-inflammatory impact in the carrageenan-induced paw edema model.
DISCUSSION: This was evident from the significant reduction in paw edema, which was equivalent to the effect of the standard anti-inflammatory medicine, Diclofenac sodium.
CONCLUSION: In summary, transethosomes, as a whole, might potentially serve as an effective method for delivering drugs via the skin. This could improve the ability of ATV to reduce inflammation by increasing its absorption through the skin.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. 

CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20-lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals [see Warnings and Precautions (5.1)] . 

Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. 

Abiraterone acetate decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of abiraterone acetate on serum testosterone levels.

Changes in serum prostate specific antigen (PSA) levels may be observed but have not been shown to correlate with clinical benefit in individual patients.
Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
Irinotecan 160 mg/m\^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.